Class I reimbursement

Sat, 21/04/2007 - 12:35pm -- Inneke Van de Vijver

DaTSCAN has successfully passed its individual revision of Class I reimbursement.

A pharmaco-economic model, evaluating the cost effectiveness of adding DaTSCAN (¹²³I-FP-CIT) SPECT to the diagnostic workup had been developed. As the model was developed before application of the diagnostic technique in real practice, a predictive validity assessment was performed based on data from a large nationwide patient registry in these patients. Good correspondence between assumed and observed changes in patient management was found, indicating that ¹²³I-FP-CIT SPECT is influential in diagnosis and management of patients with uncertain clinical diagnosis of parkinsonism. This can be achieved at a marginal added cost to the health insurance and leads to a significant gain in adequately treated years.

Read more about the model.

DaTSCAN is a radiopharmaceutical agent containing Ioflupane (¹²³I) in development for a proposed indication of the detection of loss of functional nigrostraiatal dopaminergic neurons by single photon emission computed tomography (SPECT) imaging in patients presenting with symptoms or signs suggestive of dopaminergic degeneration

Read more about datscan.